A share price of Recursion Pharmaceuticals Inc [RXRX] is currently trading at $6.4, up 9.59%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The RXRX shares have gain 21.21% over the last week, with a monthly amount glided 25.24%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Morgan Stanley started tracking the stock with Equal-Weight rating on May 22, 2023, and set its price target to $8. On March 16, 2023, Needham initiated with a Buy rating and assigned a price target of $17 on the stock. KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and suggested a price target of $20 on September 16, 2022. BofA Securities downgraded its rating to a Neutral but $10 remained the price target by the analyst firm on April 18, 2022. SVB Leerink downgraded its rating to Mkt Perform for this stock on March 04, 2022, but kept the price target unchanged to $10. In a note dated September 21, 2021, Berenberg initiated an Buy rating and provided a target price of $37 on this stock.
Recursion Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $3.79 and $12.36. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. Recursion Pharmaceuticals Inc [NASDAQ: RXRX] shares were valued at $6.4 at the most recent close of the market. An investor can expect a potential drop of -6.25% based on the average RXRX price forecast.
Analyzing the RXRX fundamentals
Trailing Twelve Months sales for Recursion Pharmaceuticals Inc [NASDAQ:RXRX] were 59.79M which represents 6.89% growth. Gross Profit Margin for this corporation currently stands at -0.0% with Operating Profit Margin at -9.61%, Pretax Profit Margin comes in at -9.63%, and Net Profit Margin reading is -9.62%. To continue investigating profitability, this company’s Return on Assets is posted at -0.44, Equity is -0.75 and Total Capital is -0.49. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Recursion Pharmaceuticals Inc [NASDAQ:RXRX] is 4.11. Further, the Quick Ratio stands at 4.11, while the Cash Ratio is 3.52. Considering the valuation of this stock, the price to sales ratio is 46.25, the price to book ratio is 2.78.
Transactions by insiders
Recent insider trading involved Gibson Christopher, Chief Executive Officer, that happened on Mar 27 ’25 when 0.14 million shares were sold. Officer, Gibson Christopher completed a deal on Mar 27 ’25 to buy 0.14 million shares. Meanwhile, Chief Executive Officer Gibson Christopher sold 20000.0 shares on Mar 05 ’25.
